Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG Logo
Lonza Group AG
SIX:LONN
Watchlist
Price: 557.4 CHF 2.54% Market Closed
Market Cap: 39.1B CHF

Operating Margin

14.8%
Current
Declining
by 3.5%
vs 3-y average of 18.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
14.8%
=
Operating Income
CHf1B
/
Revenue
CHf7.1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
14.8%
=
Operating Income
CHf1B
/
Revenue
CHf7.1B

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Lonza Group AG
SIX:LONN
38.3B CHF
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
240.3B USD
Loading...
US
Danaher Corp
NYSE:DHR
171B USD
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
281.9B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
39.6B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83.8T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.5B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.8B EUR
Loading...
US
Illumina Inc
NASDAQ:ILMN
23.3B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in Switzerland
Percentile
65th
Based on 1 083 companies
65th percentile
14.8%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Lonza Group AG
Glance View

Amidst the serene valleys and bustling innovation hubs of Switzerland, Lonza Group AG has carved an indelible niche in the dynamic world of life sciences. Established in 1897, this stalwart of the biotech and pharmaceutical industry seamlessly blends traditional Swiss precision with cutting-edge scientific inquiry. Originally a chemical company, Lonza has reinvented itself over the years, today standing as a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and nutrition sectors. From delivering small molecules and complex biologics to pioneering innovations in cell and gene therapy, Lonza's versatile and expansive portfolio underscores its core strength: fostering the seamless transition from early-stage research to full-scale manufacturing. This unique capability leverages a vast network of state-of-the-art facilities and expert talent, enabling Lonza to nurture groundbreaking therapies from concept through to market readiness. The secret to Lonza's business model lies in its adept mix of contract development and manufacturing (CDMO) services, enabling it to partner with a diverse clientele ranging from nimble biotechs to giant pharmaceutical firms. This breadth of collaboration adds a layer of stability and scale to its operations, generating revenue through long-term manufacturing agreements and comprehensive development programs. Lonza thrives on its ability to tailor its offerings, providing customized support at various stages of a drug’s lifecycle — from early discovery to commercial supply. Furthermore, their expansion into high-growth areas such as personalized medicine and biotechnology bolsters their competitive edge while aligning with market demand trends. This strategic alignment, coupled with a relentless pursuit of operational excellence and innovation, propels Lonza's enduring legacy as both a powerhouse and a partner in forging the future of medicine.

LONN Intrinsic Value
719 CHF
Undervaluation 22%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
14.8%
=
Operating Income
CHf1B
/
Revenue
CHf7.1B
What is Lonza Group AG's current Operating Margin?

The current Operating Margin for Lonza Group AG is 14.8%, which is below its 3-year median of 18.3%.

How has Operating Margin changed over time?

Over the last 3 years, Lonza Group AG’s Operating Margin has decreased from 20.2% to 14.8%. During this period, it reached a low of 13.1% on Jun 30, 2024 and a high of 22.7% on Jun 30, 2023.

Back to Top